SCHEMBL23607124

SCHEMBL23607124

O=C(Nc1nc2ccccc2s1)c1ccccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.71
ALDH1A1 P00352 2/20 0.69
NPC1 O15118 9/20 0.67
RAB9A P51151 9/20 0.67
MEN1 O00255 6/20 0.67
KMT2A Q03164 6/20 0.67
PKM P14618 1/20 0.67
PAX8 Q06710 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
TOP1 P11387 2/20 0.67
DHODH Q02127 1/20 0.62
RXFP1 Q9HBX9 1/20 0.62
ADORA1 P30542 2/20 0.61
DYRK1A Q13627 1/20 0.61
CASP3 P42574 4/20 0.60
SENP8 Q96LD8 4/20 0.60
SENP7 Q9BQF6 4/20 0.60
SENP6 Q9GZR1 4/20 0.60
KDM4E B2RXH2 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2242970 0.84 CNR1 (0.69) CNR1ALDH1A1NPC1RAB9AMEN1
SCHEMBL4912955 0.84 DHODH (0.76) CNR1ALDH1A1NPC1RAB9AMEN1
SCHEMBL4918642 0.84 HTT (0.76) CNR1ALDH1A1NPC1RAB9AMEN1
SCHEMBL30553297 0.84 RAB9A (0.70) CNR1ALDH1A1NPC1RAB9AMEN1
SCHEMBL19194695 0.84 SCD (0.66) CNR1ALDH1A1NPC1RAB9AMEN1
SCHEMBL17433366 0.84 TOP1 (0.64) CNR1ALDH1A1NPC1RAB9AMEN1
SCHEMBL17770342 0.84 DHODH (0.76) CNR1ALDH1A1NPC1RAB9AMEN1
SCHEMBL17178426 0.84 RAB9A (0.69) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL22130163 0.84 RAB9A (0.69) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL13236116 0.84 NPC1 (0.76) ALDH1A1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103415-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 US disclosed
WO-2021133917-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103415-A1 SMARCA INHIBITORS AND USES THEREOF SMARCC1, SMARCE1, SMARCA1 CNR1 4708/4885ALDH1A1 3416/4885NPC1 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.